Tema Oncology ETF
CANC - ETF AI Analysis
Top Page
Tema Oncology ETF (CANC)
CANC, the Tema Oncology ETF, has a solid but not top-tier rating, reflecting a mix of strong established pharma leaders and riskier biotech names. High-quality holdings like Merck, Novartis, Eli Lilly, and Exelixis, all supported by robust financial performance and promising drug pipelines, are key positives that lift the fund’s quality. However, weaker positions such as Cogent Biosciences and some loss-making or overvalued biotechs introduce higher risk, and the fund’s focus on oncology means it is concentrated in a single, often volatile sector.
CANC vs. SPDR S&P 500 ETF (SPY)
- AUM
- 212.25M
- Region
- Global
- Expense Ratio
- 0.75%
- Beta
- 0.73
- Issuer
- Tema
- Inception Date
- Aug 15, 2023
- Dividend Yield
- 0.05%
- Asset Class
- Equity
- Index Tracked
- No Underlying Index
CANC Summary
The Tema Oncology ETF (ticker CANC) is a fund that focuses on companies involved in cancer research and treatment, mainly in the U.S. health care sector. It does not track a traditional index, but instead follows the theme of oncology, investing in drug makers and biotech firms working on new cancer therapies. Well-known holdings include Merck & Company and Eli Lilly, along with smaller, specialized biotech companies. Someone might invest in this ETF for potential long-term growth and to support innovation in cancer care. A key risk is that biotech and pharma stocks can be very volatile, so the fund’s value can go up and down sharply.
How much will it cost me?
This ETF has an expense ratio of 0.75%, which means you’ll pay about $7.50 per year for every $1,000 you invest. That’s higher than the average ETF because it’s actively managed and focuses on a specialized niche in oncology rather than tracking a broad, low-cost index.
What would affect this ETF?
This oncology-focused ETF could benefit if major drug makers like Eli Lilly, Merck, Novartis, and AbbVie successfully launch new cancer treatments, if global health care spending grows, and if supportive regulations speed up approvals for innovative therapies. On the negative side, setbacks in clinical trials, stricter drug pricing rules, or a weaker global economy that pressures health care budgets could hurt the fund, especially given its heavy concentration in a single, volatile niche of the health care sector.
CANC Top 10 Holdings
This oncology-focused ETF is heavily tilted toward health care, with big drugmakers like Merck, Eli Lilly, Novartis, and AbbVie providing the steady backbone of performance as their cancer franchises keep humming along. Genmab and Halozyme are the fund’s real bright spots, rising on strong results and upbeat outlooks. On the flip side, Cogent Biosciences has been lagging, acting like a small anchor on an otherwise upbeat portfolio. With a global mix of U.S. and European names, the fund is concentrated in oncology innovators rather than any single country.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Genmab | 5.83% | $12.26M | $30.47B | 69.87% | 76Outperform | |
| Revolution Medicines | 5.44% | $11.44M | $37.27B | 167.61% | 52Neutral | |
| Eli Lilly & Co | 5.53% | $11.63M | $1.36T | 41.12% | 72Outperform | |
| Merck & Company | 4.98% | $10.47M | $364.26B | 59.00% | 80Outperform | |
| Cogent Biosciences | 4.37% | $9.19M | $4.97B | -15.58% | 37Underperform | |
| BeOne Medicines | 4.31% | $9.07M | $46.69B | 13.08% | 61Neutral | |
| Novartis AG | 4.20% | $8.83M | CHF 245.40B | 26.78% | 80Outperform | |
| AbbVie | 3.85% | $8.10M | $521.50B | 27.01% | 66Neutral | |
| Exelixis | 3.77% | $7.93M | $16.84B | 62.93% | 78Outperform | |
| BridgeBio Pharma | 3.18% | $6.69M | $15.25B | 20.35% | 59Neutral |
CANC Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For CANC, the sentiment is Negative. The current price of 41.06 is below the 20-day moving average (MA) of 41.79, below the 50-day MA of 41.56, and above the 200-day MA of 39.54, indicating a neutral trend. The MACD of 0.12 indicates Positive momentum. The RSI at 46.36 is Neutral, neither overbought nor oversold. The STOCH value of 31.07 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CANC.
CANC Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| $41.06 | $44.00(7.16% Upside) | $212.25M | 0.75% | 61Neutral | |
| $47.09 | $52.06(10.55% Upside) | $895.31M | 0.17% | 66Neutral | |
| $49.96 | $82.00(64.13% Upside) | $827.94M | 0.70% | 56Neutral | |
| $28.93 | $32.23(11.41% Upside) | $720.68M | 0.70% | 68Neutral | |
| $33.28 | $43.70(31.31% Upside) | $701.68M | 0.75% | 70Neutral | |
| $29.22 | $44.19(51.22% Upside) | $657.99M | 0.75% | 59Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| CANC | Tema Oncology ETF | 41.06 | 7.50 | 22.33% | |
| AVRE | Avantis Real Estate ETF | 47.09 | 4.61 | 10.84% | |
| BLOK | Amplify Transformational Data Sharing Etf | 49.96 | -7.74 | -13.42% | |
| CSRE | Cohen & Steers Real Estate Active ETF | 28.93 | 3.76 | 14.92% | |
| VOLT | Tema Electrification ETF | 33.28 | 4.22 | 14.52% | |
| ARKX | ARK Space Exploration & Innovation ETF | 29.22 | 2.11 | 7.78% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
